DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
CN |
|
Nkarta Inc
NASDAQ:NKTX
|
US |
|
MetLife Inc
NYSE:MET
|
US |
|
Franklin Electric Co Inc
NASDAQ:FELE
|
US |
|
Regions Financial Corp
NYSE:RF
|
US |
|
Pro Medicus Ltd
ASX:PME
|
AU |
|
Paycom Software Inc
NYSE:PAYC
|
US |
|
UiPath Inc
NYSE:PATH
|
US |
|
Loncin Motor Co Ltd
SSE:603766
|
CN |
|
PhosAgro PAO
MOEX:PHOR
|
RU |
|
Assystem SA
PAR:ASY
|
FR |
|
Builders FirstSource Inc
NYSE:BLDR
|
US |
|
Texas Pacific Land Corp
NYSE:TPL
|
US |
Wall St Price Targets
Price Targets Summary
DaShenLin Pharmaceutical Group Co Ltd
According to Wall Street analysts, the average 1-year price target for DaShenLin Pharmaceutical Group Co Ltd is 25.22 CNY with a low forecast of 23.23 CNY and a high forecast of 28.04 CNY.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DaShenLin Pharmaceutical Group Co Ltd's stock price target?
Price Target
25.22
CNY
According to Wall Street analysts, the average 1-year price target for DaShenLin Pharmaceutical Group Co Ltd is 25.22 CNY with a low forecast of 23.23 CNY and a high forecast of 28.04 CNY.
What is the Revenue forecast for DaShenLin Pharmaceutical Group Co Ltd?
Projected CAGR
10%
Over the last 10 years, the compound annual growth rate for Revenue has been 18%. The projected CAGR for the next 3 years is 10%.
What is the Operating Income forecast for DaShenLin Pharmaceutical Group Co Ltd?
Projected CAGR
19%
Over the last 10 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 2 years is 19%.
What is the Net Income forecast for DaShenLin Pharmaceutical Group Co Ltd?
Projected CAGR
16%
Over the last 10 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 3 years is 16%.
